ExploreWatchlistsPricing
  1. JP-listed companies
  2. SanBio Company Limited
  3. Financials
  4. Earnings per share

SanBio Company Limited (4592)

Market cap
¥154.3B
P/E ratio
-27.4x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEarnings per share (JPY)YoY (%)
Jan 31, 2026-52.5+25.54%
Jan 31, 2025-41.9+3.41%
Jan 31, 2024-40.5-57.83%
Jan 31, 2023-96+6.27%
Jan 31, 2022-90.3+38.16%
Jan 31, 2021-65.4-35.21%
Jan 31, 2020-100.9+67.71%
Jan 31, 2019-60.2-30.72%
Jan 31, 2018-86.8+112.45%
Jan 31, 2017-40.9+80.33%
Jan 31, 2016-22.7-151.16%
Jan 31, 201544.3-387.54%
Jan 31, 2014-15.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat